

Index

- Absolute risk reduction (ARR), concepts, 116
- Acupuncture, 156
- Adaptive randomization procedure, concepts, 60–2
- ADHD, *see* Attention-deficit/hyperactivity disorder (ADHD)
- Adherence, 36
see also Compliance issues
- Adherers-only approach, 109–12
- AIDS, 31, 37
- Allocation issues, *see* Assignment issues
- Alternative allocations, clinical trials, 18–21
- Alternative therapies, 33, 155–8
- Altman, D., 90–2, 95, 195–9
- American Journal of Psychiatry* (AJP), 62
- American Psychiatric Association, 161
- Amitriptyline, 157–8
- Analyses, 64, 66–70, 89–117, 119–44, 154–62, 163–80, 182–93, 200, 202–3
baseline data, 91–7, 123–44
Beating the Blues analysis example, 119–44
cost-effectiveness analysis, 113–15, 185–6
design considerations, 89, 182–93, 200
dropouts, 49–50, 98, 103–7, 111–12, 117, 119–44, 202–3
economic evaluations, 112–15
examples, 119–44, 154–62
imputation techniques, 105–7, 202–3
intention-to-treat analysis, 78, 109–12, 117, 176
interim analyses, 66–70, 182–93, 202–3
longitudinal data, 64, 97–103, 117, 119–44
meta-analyses, 43–4, 66, 145–62, 178
multiple outcome measures, 108–9, 120–44, 151–2
number needed to treat, 116
post-treatment BDI scores example, 123–35
psychiatric trials, 89–117, 119–44, 154–62, 163–80, 200
statistical issues, 89–117, 119–44, 200
- Analysis of covariance, concepts, 60, 95–103, 117, 126–44
- Anecdotal evidence
critique, 13–15
see also Case series
- Anorexia nervosa, 63–4
- Antidepressants, 10, 22, 30–2, 47, 61, 80, 84–6, 103, 119–20, 150–1, 156–8, 176–7
critique, 31–2, 47, 84, 176–7
ethical issues, 30–2, 47
meta-analyses, 150–1, 156–8
outcome measures, 84
- Antihistamine promethazine, 10
- Antimony, 6–7
- Antipsychotic agents, 27, 31
- Antiretroviral agents, 67
- Antman, E., 43
- Anxiety, 10, 11, 22, 166–7
- Aortic valve surgery, 178
- Appelbaum, Paul, 161
- Appendices, 181–203
- Areas under the curve, 87, 98–9
- Aretaeus, 6
- Artefactual causes, heterogeneity, 154–6
- Arthritis, 14, 86–7
- Asher, Richard, 33
- Aspirin, 5, 178
- Assessments, treatments, 1–11

- Assignment issues, 17, 18–24, 48–62, 196–200
 blinding, 25–6, 74–6
 concealment considerations, 23, 25–6, 62, 176, 199–200
 flawed allocations, 18–20
 Zelen's design, 48–51
- Asthma, 14
- Asylums, 6–8, 14, 20
- Attention-deficit/hyperactivity disorder (ADHD), 55
- Audits, 178
- Authors, conflicts of interest, 170–1
- Autistic disorder, 45–6
- Bacterial meningitis, 13, 29
- Balfour, Thomas, 20
- Baseline data
 comparability uses, 92, 96–7
 concepts, 91–7, 123–44
 covariate-adjusted analysis, 92, 93–6
 outcome measures, 91–7, 123–44
 subgroup analysis, 91–3, 123–44
- BDI, *see* Beck Depression Inventory (BDI)
- Beating the Blues analysis example, 119–44
- Beck Depression Inventory (BDI), 78, 120–44
 analysis example, 120–44
 concepts, 78, 120–44
 post-treatment BDI scores example, 123–35
- Behavioural psychotherapy, historical background, 11
- Belladonna, 20
- Benchmarking, 40–1
- Benzodiazepines, 10
- Berry, D.A., 34–5
- Bethlem Hospital, 6
- Biases, concepts, 14–15, 17, 18–19, 22–4, 25, 48–50, 76, 85–6, 146–7, 151–3, 158–61, 173–4, 176, 179
- Bipolar disorder, 6, 8–9, 10, 73, 177
- Bivariate normal distributions, 102–3
- BJP, *see* *British Journal of Psychiatry* (BJP)
- Blane, Gilbert, 4
- Blinding
 concepts, 25–6, 44, 74–6, 79, 113, 149–50, 156–8, 180
 costs, 113
 critique, 26, 79
 definition, 25
 degrees, 26
 historical background, 25
 randomized clinical (controlled) trials, 25–6, 44, 74–6, 79, 113, 149–50, 156–8, 180
see also Double-blind studies; Single-blind studies; Triple-blind studies
- Blocked randomization
 concepts, 57–8, 61
 critique, 58
- Blood
 circulation of the blood, 2
 pressure, 94, 104
- Blood-letting, historical treatments, 2, 5, 6, 14, 19, 20
- Body mass index (BMI), 104–5
- Bondareff *et al*, 45
- Bonferroni procedure, 108–9
- Breadth selection component, meta-analyses, 148–9
- Breast cancer, 170
- Brief Psychiatric Rating Scale, 91
- British Journal of Psychiatry* (BJP), 62
- British Medical Journal* (BMJ), 50–1, 191
- BtB, *see* Beating the Blues analysis example
- Budgets, 112, 185–93
- Byar, D.P., 175
- Cade, John, 10
- Campbell, M., 81
- Cancers, 51, 70, 166, 170
- Cardiac arrest, 13, 176
- Cardiology 'mega trials', 176
- Carpenter *et al*, 142
- Carryover effects, 45–6
- Case record forms (CRFs), 187–8
- Case series, 13
see also Anecdotal evidence
- CATIE trial, 27
- Cawley, Robert, 22
- CBT, *see* Cognitive behavioural therapy (CBT)
- Central randomization, allocation concealment, 62
- CFS, *see* Chronic fatigue syndrome (CFS), treatments
- Challenges, clinical trials, 163–80
- Chalmers, I., 19–20, 33, 43
- Chalmers, T.C., 146–7
- Change scores, 92, 93–6, 117, 126–44
- Charismatic doctors, 14
- Charles II, King of England, 2–3
- Chen *et al*, 96
- Cheney, Dr, 8–9
- Chi-square tests, 144
- Childhood depression, SSRIs, 172
- Chloral, 6–7
- Chlorpromazine, 10, 11, 22
- Chronic fatigue syndrome (CFS), treatments, 26
- Cigarette smoking, 51, 96
- Clinical freedom, critique, 33
- Clinical governance, 32–3, 188–90, 193
- Clinical trials
 aims, 44
 alternative allocations, 18–21
 analyses, 64, 66–70, 89–117, 119–44, 154–62, 163–80, 182–93, 200, 202–3
 assignment issues, 17, 18–24, 48–62, 196–200
 Beating the Blues analysis example, 119–44

- blocked randomization, 57–8, 61
- challenges, 163–80
- characteristics, 5
- cluster trials, 51–3
- complete randomization, 56–7
- complex interventions, 79–81, 166–8, 174
- compliance issues, 36–40, 46, 186–7
- components, 17
- computer software, 61, 68, 106, 120–44, 201–3
- concepts, 4–5, 10–11, 13–41, 44–70, 163–80, 181–93, 201–3
- conflicts of interest, 164, 170–1
- control groups, 17–24, 44–5, 56–62, 149–50, 169–70, 179–80, 182–93
- cost-effectiveness analysis, 113–15, 185–6
- costs, 112–15, 185–6
- critique, 17, 21, 29–33, 40–1, 71–87, 163–80, 195–6
- crossover trials, 45–6, 110–11
- defences, 178–80
- definition, 17
- depression, 22, 30–2, 45, 76–8, 119–44, 155–62, 166–7, 172–3, 175, 176–7
- design considerations, 23, 37–8, 41, 43–70, 181–93, 202–3
- developing countries, 31, 163–4, 173
- drugs, 27–9, 30, 79, 164, 170–3
- duration issues, 66–70, 71–2, 74, 140–4, 178, 182–93
- economic evaluations, 112–15
- ethical issues, 17, 21, 29–33, 41, 46–8, 66, 67–70, 163–4, 188
- examples, 119–44, 154–62
- factorial designs, 46
- first modern trials, 20–2
- fraud, 163–4
- future prospects, 163–4, 173–80
- historical background, 4–5, 10–11, 15–16, 19–24, 176
- Horton's paper, 163–4, 178–9
- 'how to do it' guide, 181–93
- informed consent, 21, 30, 33–6, 48–51, 164, 178–80, 189–90
- interim analyses, 66–70, 182–93, 202–3
- justification debate, 164–9
- management issues, 181–93
- minimization method, 60–2
- mortality endpoints, 69, 82
- multicentre trials, 29, 53–5, 123–44, 185
- N-of-1 trials, 55
- necessity debate, 169–70
- outcome measures, 17, 26, 44, 64–5, 81–7, 91–117, 120–44, 151–2, 184–93, 195–200
- parallel groups, 44–5
- patient preference trials, 46–8, 78, 169
- public perceptions, 163–4, 171–3, 180
- recruitment issues, 29, 44, 61–2, 63–6, 72–3, 74, 77, 174, 180, 190
- registration issues, 161–2
- scandals, 163–4, 171–3, 180
- size issues, 61–2, 63–6, 74, 77, 174–8, 182–93, 196–200, 202–3
- specialist settings, 73, 76–8
- staff factors, 38, 112–15, 179, 185–6
- stratified randomization, 58–61
- termination issues, 66–70
- threats, 163–80
- time factors, 64, 66–70, 71–2, 74, 86–7, 97–103, 120–44, 182–93
- toxicity, 27–8
- transparency issues, 172–3, 179
- treatment groups, 17–24, 44–55, 91–7
- trial protocol, 70, 181–93
- trial reports, 195–200
- types, 27–9, 45–55
- 'wrong' answers, 175–6
- Zelen's design, 48–51
- see also* Psychiatric trials; Randomized clinical (controlled) trials (RCTs)
- Clinton, Bill, 66
- Cluster trials
 - concepts, 51–3
 - critique, 52
 - examples, 52–3
- Co-morbid disorders, 74–7, 166–8
- Cochrane, Archie, 22, 179
- Cochrane Collaboration, 24, 73, 147–50, 168, 181, 192
- Cochrane Reviews, 73, 181
- Cochrane Schizophrenia Database, 168
- Cognitive behavioural therapy (CBT)
 - computer software, 120–44
 - concepts, 40, 48, 78–9, 114, 119–44
 - cost-effectiveness analysis, 113
 - depression, 119–44
 - interactive systems, 120–44
 - staff shortages, 119–20
- Cognitive therapy, historical background, 11
- Collaborations viewpoint, 180
- 'Collect less data from more people' motto, 37
- Collective/individual conflicts, ethical issues, 30–1
- Committees, interim analyses, 69
- Common cold, 20
- Community care, hospital care, 69–70, 73, 177
- Comparability uses, baseline data, 92, 96–7
- Competing treatments, concepts, 4–5, 16
- Complementary medicines, 156–8
- Complete-case analysis, dropouts, 105–6, 137
- Complete randomization, concepts, 56–7

- Complex interventions
 concepts, 79–81, 166–8, 174
 definition, 79
 jargon, 79–80
- Complex problems, psychiatric trials, 71–2, 79–81, 135–44, 166–8, 174
- Compliance issues
 ‘collect less data from more people’ motto, 37
 concepts, 36–40, 46, 186–7
 counselling, 46
 delinquency factors, 40
 dependencies, 37
 HIV/AIDS patients, 37
 improvement methods, 37–8
 laboratory determinations, 39
 monitoring needs, 38–9
 pill/capsule counts, 39
 psychiatric trials, 39–40, 46
 staff factors, 38
 tests on blood/urine, 39
- Compliance therapy, concepts, 40, 46
- Computer software, 61, 68, 106, 120–44, 201–3
 CBT, 120–44
 databases, 149–51, 156–7, 158–62, 181, 186–7, 201–3
 GLLAMM software, 143
 imputation techniques, 106, 202–3
 interactive systems, 120–44
 interim analyses, 68, 202–3
 minimization method, 61
- Concealment considerations
 concepts, 23, 25–6, 62, 176, 199–200
 definition, 25
 historical background, 25
 methods, 62, 199–200
 quality assessments, 25
- Confidence intervals
 concepts, 90–1, 125–44, 153–60
 definition, 90–1
- Confidentiality issues, 35
- Conflicts of interest, 164, 170–1
- Confounders
 concepts, 14–15, 23–4, 48
 gender issues, 23
- Consent issues, 21, 30, 33–6, 48–51, 87, 164, 178–80, 189–90
 concepts, 33–6, 48–51, 164, 178–80, 189–90
 tracing consent, 87
 Zelen’s design, 48–51
see also Informed consent
- CONSORT Statement, 71, 192, 196–200
- ‘Consumer’ involvement, future prospects, 174
- Control groups
 concepts, 17–24
 definition, 17
 randomization techniques, 19–23, 44–5, 56–62, 149–50, 169–70, 179–80, 182–93
- Controlled clinical trials
 historical background, 5, 10–11
see also Clinical trials
- Copas, J.B., 153, 160
- Corium, 6–7
- Coronary Care Unit, Oxford, 176
- Cost-effectiveness analysis
 concepts, 113–15, 185–6
 definition, 113–14
- Costs, 112–15, 185–6
 blinding, 113
 definitions, 112–13
 economic evaluations of trials, 112–15
 types, 112–13, 185–6
- Cotton, Dr Henry A., 7–9
- Counselling, 46, 48, 78
- Covariance, 60, 92, 93–103, 117, 126–44
- Covariate-adjusted analysis, baseline data, 92, 93–6
- Cox, Sir David, 41
- CRASH-1 trial, 50
- CRFs, *see* Case record forms (CRFs)
- Criminality, mental disorders, 167
- Crossover trials, concepts, 45–6, 110–11
- CUtLASS trial, 27
- ‘Cynically relevant difference’, 64–5
- Daily Living Programme (DLP), 69–70
- DAR, *see* Dropout at random (DAR)
- Data collection, 85, 89–117, 119–44, 176–9, 186–8, 201–3
see also Statistics
- ‘Data-dredging’, 142
- Data management software, 201–3
- Data measures, *see* Outcome measures
- Data-Monitoring Committees (DMCs), 69–70, 188
- Databases, 149–51, 156–7, 158–62, 181, 186–7, 201–3
 meta-analyses, 149–51, 156–7, 158–62, 181
 systematic reviews, 149–51, 156–7, 181
see also Computer software
- Davies, David, 22
- DCAR, *see* Dropout completely at random (DCAR)
- Debriefing, concepts, 24, 30
- Declaration of Helsinki, 29, 36, 50, 192
- Defences, clinical trials, 178–80
- Delinquency factors, compliance issues, 40
- Dementia, 86
- Department of Health and Human Services, US, 50
- Depression, 3, 6, 8–9, 10, 11, 13–14, 17, 22, 30–2, 45, 47, 73, 76–8, 82–6, 119–44, 150–1, 155–62, 166–7, 172–3, 175–7
 alternative therapies, 155–8
 analysis example, 119–44, 155–62
 BDI, 78, 120–44

- Beating the Blues analysis example, 119–44
- CBT, 119–44
- childhood depression, 172
- clinical trials, 22, 30–2, 45, 76–8, 119–44, 155–62, 166–7, 172–3, 175, 176–7
- common problem, 176
- complex classifications, 76–7
- diagnostic criteria, 85–6, 150–1, 157, 168
- ECT, 9, 22
- GP training, 170
- HRSD, 85–6, 157–8
- meta-analyses, 150–1, 155–62
- outcome measures, 82–4, 120–44, 176–7
- pragmatic trials, 77–8
- primary care settings, 73, 76–8, 120, 123, 139–44
- questionnaire measures, 82
- St John's wort, 156–8, 175
- self-rated questionnaires, 86
- SSRIs, 10, 172, 176
- symptoms, 14
- transcranial magnetic stimulation, 158–60
- treatments, 9, 10, 11, 13, 17, 22, 30–2, 45, 47, 61, 73, 76–8, 82–6, 119–44, 150–1, 155–62, 166–7, 172–3, 175, 176–7
- tricyclic antidepressants, 10, 157–8, 176–7
- types, 76, 157, 166–7
- Der Simonian *et al.*, 195–6
- Design considerations
- analyses, 89, 182–93, 200
 - blocked randomization, 57–8, 61
 - clinical trials, 23, 37–8, 41, 43–70, 181–93, 202–3
 - cluster trials, 51–3
 - complete randomization, 56–7
 - concepts, 43–70, 181–93, 202–3
 - crossover trials, 45–6, 110–11
 - ethical issues, 46–8, 66, 67–70, 188
 - factorial designs, 46
 - interim analyses, 66–70, 182–93, 202–3
 - minimization method, 60–2
 - multicentre trials, 29, 53–5, 123–44, 185
 - N-of-1 trials, 55
 - parallel groups, 44–5
 - patient preference trials, 46–8, 78, 169
 - size issues, 61–2, 63–6, 74, 77, 174–8, 182–93, 196–200, 202–3
 - stratified randomization, 58–61
 - trial protocol, 70, 181–93
 - Zelen's design, 48–51
- Developing countries
- clinical trials, 31, 163–4, 173
 - HIV/AIDS trials, 31
- Dexamethasone, 158
- Diabetes, 86, 108, 116
- Diagnostic criteria, 74–7, 84–6, 150–1, 157, 165–8
- Diggle–Kenward model, 107, 143–4
- Digitalis, 6–7
- Digoxin, 5
- Diphtheria, 11
- Direct costs, concepts, 112–15, 185–6
- Directives, EU, 50, 174, 189
- Disabilities, 83–4
- DLP, *see* Daily Living Programme (DLP)
- DMCs, *see* Data-Monitoring Committees (DMCs)
- Doll, Sir Richard, 21
- Dopamine, 11
- Dose-escalation experiments, 28
- Double-blind studies
- concepts, 26, 79, 156–8, 170–1
 - see also* Blinding
- Double standards, 21
- Down's syndrome, 96
- Dropout at random (DAR), 104, 142–4
- Dropout completely at random (DCAR), 103–7, 142–4
- Dropouts, 49–50, 98, 103–7, 111–12, 117, 119–44, 149–50, 202–3
- analysis possibilities, 105–7, 119–44, 202–3
 - Beating the Blues analysis example, 142–4
 - complete-case analysis, 105–6, 137
 - concepts, 103–7, 111–12, 117, 119–44, 149–50, 202–3
 - Diggle–Kenward model, 107, 143–4
 - graphical explorations, 142–4
 - imputation techniques, 105–7, 202–3
 - intention-to-treat analysis, 111–12
 - longitudinal data, 103–7, 123–44
 - random effects models, 107, 142–4
 - summary measure approach, 107
 - types, 103–7
- Drugs, 5, 6–7, 10–11, 20–1, 26–9, 30, 47, 164, 170–3
- clinical trials, 27–9, 30, 79, 164, 170–3
 - compliance issues, 36–7, 46
 - conflicts of interest, 164, 170–1
 - dose-escalation experiments, 28
 - historical background, 5, 6–7, 10–11, 20–1
 - patient preference trials, 46–8
 - postmarketing surveillance, 28, 79–80
 - side effects, 26, 27–8, 187–8
 - suspensions, 164, 170–1
 - TGN 1412 trial, 164, 171–3
 - see also* Pharmacology
- DSM assessments, 77, 157
- Duration considerations, clinical trials, 66–70, 71–2, 74, 140–4, 178, 182–93
- Duval, S., 151–2
- Dysthymia, 76, 168
- see also* Depression
- Eating disorders, 63–4
- see also* Anorexia nervosa
- Economic evaluations, clinical trials, 112–15

- Effectiveness trials
 concepts, 27–8, 43–4, 72–8, 112–15, 168–9
 psychiatric trials, 73–8, 112–15, 168–9
 quality assessments, 73
see also Pragmatic trials
- Efficacy trials
 concepts, 27–8, 31–2, 43–4, 72–8, 168–9
 psychiatric trials, 73–8, 168–9
 quality assessments, 73
see also Explanatory trials
- Efron, B., 36, 110–11
- Electrophysiological measures, critique, 86
- Elkes, Charmain, 22
- Elkes, Joel, 22
- EMBASE, 158
- Emetics, 2
- Empiricism, historical background, 7–11
- Endoscopic therapy, 43
- Enemas, historical treatments, 2
- Epileptic fits, 9–10
- Equipose state, 29–30, 46–8
- Ethical issues
 antidepressants, 30–2, 47
 clinical governance, 32–3, 188–90, 193
 clinical trials, 17, 21, 29–33, 41, 46–8, 66, 163–4, 188
 concepts, 29–33, 41, 46–8, 66, 67–70, 188
 design considerations, 46–8, 66, 67–70, 188
 duration considerations, 66–70
 HIV/AIDS in developing countries, 31
 individual/collective conflicts, 30–1
 informed consent, 21, 30, 33–6, 164, 189–90
 interim analyses, 67–70, 188
 placebo effects, 30–1
 randomized clinical (controlled) trials, 21, 29–33, 35–6, 41, 46–8, 66, 67–70, 163–4, 188
 Zelen's design, 50–1
- European Union (EU), 50, 174, 177–8, 189–90
- Evaluations
 economic evaluations, 112–15
 treatments, 4–5, 10–11, 13, 28–41, 79–81, 112–15
see also Clinical trials
- Evans, Timothy, 161
- Evidence-based medicine
 concepts, 11, 13–41
 critique, 13–14
see also Clinical trials
- Exorcisms, 6
- Expectant mothers, smoking, 51, 96
- Experimentation
 concepts, 1–2, 13–14, 15–16, 19–22
 historical background, 1–2, 15–16, 19–22
 needs, 15–16
see also Clinical trials
- Explanatory trials
 concepts, 27, 32, 72–8, 168–9
 critique, 32, 72–8, 168–9
 eligibility criteria, 72–3
 pragmatic trials, 72–8, 168–9
see also Efficacy trials
- Exploratory trials, complex interventions, 80–1
- Eysenck, Hans, 147, 155
- Factorial designs, concepts, 46
- Families, mental illness, 82
- Familywise error (FEW), 108
- Fashions, treatments, 2
- FDA, *see* Food and Drug Administration (FDA), US
- 'Fence sitters', 81
- FEW, *see* Familywise error (FEW)
- Fisher, R.A., 19–22
- Fisher's agricultural experiments, 144
- Fixed effects models, meta-analyses, 153–5
- Fleiss, J.L., 81–2
- Fletcher, William, 20
- Fluoxetine, 173
- Focal infections, mental disorders, 7–8
- Follow-up measures, outcome measures, 87, 120–44, 191
- Food and Drug Administration (FDA), US, 50, 161, 171
- Foucault, 6
- Foxglove, 5
- Fraud, clinical trials, 163–4
- Friedman *et al*, 38–9
- Funnel plot, concepts, 151–2
- Future prospects, clinical trials, 163–4, 173–80
- Galen, 1–2
- Gardner, M.J., 90–2
- Gas, suicides, 15
- Gender issues, confounders, 23
- General practitioners (GPs), 48, 73, 76–8, 120, 123, 139–44, 170
- Glass, G., 147
- GLLAMM, 143, 203
- Gotzsche, P.C., 53
- GPs, *see* General practitioners (GPs)
- Graphical displays
 dropout exploration methods, 142–4
 longitudinal data, 124–5, 128–35
- Greenburg Report, 68–9
- Group sequential procedures, 67–8
- 'Guess masquerading as mathematics', 64–5
- Guinea pigs, 163–4, 172–3
- Haloperidol, 27, 91
- Hamilton, Alexander, 20
- Hamilton Rating Scale for Depression (HRSD), 85–6, 157–8
see also Observer-rated scales

- Hampshire Depression Project, 52–3
 Handicaps, 83–4
 Hart, Philip D'Arcy, 20
 Harvey, William, 2
 Headaches, 49–50
 Healy, D., 22
 Heart, 'pores', 1
 Helmont, Jean Baptiste van, 19
 Herbalism, 156–8
 Heroin, 49
 Heterogeneity factors, meta-analyses, 154–5, 157–8
 Hill, Austin Bradford, 20–2, 41, 57, 82, 164
 Hippocratic oath, 2
 Historical controls
 critique, 9–10, 17–18
 ECT, 9–10, 22
 HIV/AIDS, 31, 37, 67
 Homeopathic medicines, 20, 156, 175
 Horton, R., 163–4, 178
 Hospital care, community care, 69–70, 73, 177
 Hotelling's T^2 test, 108–9
 Hotopf, M., 77, 176–7
 HRSD, *see* Hamilton Rating Scale for Depression (HRSD)
 HRT, 158, 170
 'Human experience', 165–6
 Hypertension, 94
 Hypotheses
 p-values, 90–1, 93–7, 117, 125–44, 200
 Type 1/2 errors, 20, 63–8, 108, 111, 200
- IC, *see* Informed consent
 ICD assessments, 77, 157
 ICMJE, 171
 Imipramine, 157–8
 Implicit historical controls
 concepts, 18
 see also Historical controls
 Imputation techniques
 computer software, 106, 202–3
 concepts, 105–7, 202–3
 dropouts, 105–7, 202–3
 Indirect costs, concepts, 112–15, 185–6
 Individual interventions, psychiatric trials, 165–6
 Individual/collective conflicts, ethical issues, 30–1
 Infant mortality, 11
 Infections, mental disorders, 7–8
 Informed consent, 21, 30, 33–6, 48–51, 164, 178–80, 189–90
 concepts, 33–6, 48–51, 164, 178–80, 189–90
 definition, 34
 exceptions, 36, 50–1
 historical background, 33–4
 jargon, 35
 litigation, 164, 179
 randomized clinical (controlled) trials, 35–6, 48–51, 164, 178–80, 189–90
 Insanity, 6
 Institute of Psychiatry, London, 71
 Insulin coma, 8–9
 Intention-to-treat analysis (ITT)
 concepts, 78, 109–12, 117, 176
 dropouts, 111–12
 noisy phenomenon, 110–12
 Interactive systems
 CBT, 120–44
 see also Computer software
 Interim analyses
 committees, 69
 computer software, 68, 202–3
 concepts, 66–70, 182–93, 202–3
 ethical issues, 67–70, 188
 psychiatric trials, 69–70, 202–3
 statistics, 66–70, 202–3
 suicides, 69–70
 Internet
 information availability, 180
 useful web sites, 191–3, 201–3
 Intracluster correlation coefficient, 52
 Irritable bowel syndrome, 26
 ISIS trial, 176
 ITT, *see* Intention-to-treat analysis (ITT)
- Jargon
 complex interventions, 79–80
 informed consent, 35
 Justification debate, clinical trials, 164–9
- Kendell, Robert, 76
 Kirsch, I., 150
 KISS (keep it simple, stupid), 84, 168, 174–5, 185
 Kopeloff, Dr, 8–9
 Kroenke, Kurt, 177
- Laboratory determinations, compliance issues, 39
 Laborit, Henri, 10
Lancet, 173, 178
 Large simple randomized trials
 concepts, 77, 174–8
 see also Pragmatic trials
 Last observation carried forward (LOCF), 106, 112
 Latent variables, 107, 143–4
 Lau, J., 146–7
 Le Fanu, J., 89
 Leaflets giving information, compliance issues, 46
 Lehmann, Heinz, 14
 Lemons, scurvy, 4–5
 Lewis, Sir Aubrey, 21–2
 Lignocaine, 30
 Lilly, 177
 Limes, scurvy, 4–5

- Lind, James, 3, 5, 156
- Lithium, 10, 22, 177
- Litigation, 164, 179
- Lobar pneumonia, 20
- Lobotomies, 9
- Local independence assumption, 100
- LOCF, *see* Last observation carried forward (LOCF)
- Log-odds ratio, 158–60
- Logistic regression models, 103
- ‘Long’ form data, 136–7
- Longitudinal data
 - concepts, 64, 97–103, 117, 119–44
 - dropouts, 103–7, 123–44
 - graphical displays, 124–5, 128–35
 - missing values, 103–7, 123–44
 - random effects models, 99–103, 107, 117, 135–44
 - response feature analysis, 97–9, 131–44
- Louis, Pierre-Charles-Alexander, 5
- Magic, 156
- Management issues, clinical trials, 181–93
- Mania, 6, 22, 73, 158, 177
 - randomized controlled trials, 22, 73
 - treatments, 158
- Manic depression, 6, 8–9, 10, 73, 177
- Maprotiline, 157–8
- Marginal opportunity costs, 113
- Measures, *see* Outcome measures
- Medical Research Council (MRC), 20–2, 79, 184–5, 192
- Medicines for Human Use (Clinical Trials) Regulations 2004, 50
- MEDLINE, 149–50, 156–7, 158, 161
- ‘Mega silliness’, 147, 155
- Meinert, C.L., 34–5, 38, 195, 199
- Melancholic depression, 76
- Meningitis, 13, 29
- Mental disorders, 5–11, 14, 17, 74–7, 83–7, 120–44, 166–8
 - co-morbid disorders, 74–7, 166–8
 - criminality, 167
 - diagnostic criteria, 74–7, 84–6, 150–1, 157, 165–8
 - outcome measures, 83–7, 120–44
 - spontaneous improvements, 14, 17
 - see also* Individual disorders; Treatments
- Mental illness
 - families, 82
 - historical treatments, 5–11
 - outcome measures, 82–7, 120–44
 - see also* Psychiatric trials; Treatments
- Meta-analyses, 43–4, 66, 145–62, 178
 - biases, 146–7, 151–3, 159–61, 173, 179
 - breadth selection component, 148–9
 - concepts, 43–4, 66, 145–62
 - critique, 147–62
 - databases, 149–51, 156–7, 158–62, 181
 - definition, 146–7
 - depression, 150–1, 155–62
 - examples, 150–1, 154–62
 - fixed effects models, 153–5
 - funnel plot, 151–2
 - heterogeneity factors, 154–5, 157–8
 - historical background, 147
 - null hypothesis, 153
 - psychiatric trials, 154–62
 - publication bias, 151–3, 157–62, 173
 - quality selection component, 148–9
 - random effects models, 153–5
 - registration issues, 161–2
 - representativeness selection component, 148–9, 151–3
 - St John’s wort and depression, 156–8, 175
 - statistics, 153–5, 178
 - study-selection issues, 148–51, 158–9
 - success factors, 160–1
 - see also* Systematic reviews
- Meta-regression, concepts, 154–6
- Methylphenidate, 55
- Metoprolol, 39
- Minimization method
 - computer software, 61
 - concepts, 60–2
- ‘Miraculous’ cures, 13
- Missing values
 - concepts, 103–7, 123–44, 202–3
 - see also* Dropouts
- Monitoring needs, compliance issues, 38–9
- Moniz, Egas, 9
- Monro, John, 6
- Moral treatment, 6–7
- Mortality endpoints, clinical trials, 69, 82
- Motivational interviewing, 40
- MRC, *see* Medical Research Council (MRC)
- MRI scans, 49–50
- Muench, Hugo, 17
- Mulrow, C., 145–6
- Multicentre trials
 - concepts, 29, 53–5, 123–44, 185, 190
 - critique, 53–4
 - organizational issues, 53–4
 - see also* Recruitment issues
- Multiple imputation technique, 106–7
- Multiple looks, concepts, 67–70
- Multiple outcome measures
 - concepts, 108–9, 120–44, 151–2
 - see also* Outcome measures
- Myocardial infarction, 39, 43, 158, 170, 176
- N-of-1 trials, concepts, 55
- Narrative reviews, critique, 145–6
- National Institute for Clinical Excellence (NICE), 32
- Natural gas, suicides, 15

- Necessity debate, clinical trials, 169–70
- Neuropathy, 116
- Neuropsychological measures, critique, 86
- New England Journal of Medicine*, 169, 171
- NHS, 185, 187, 191–2
- NICE, *see* National Institute for Clinical Excellence (NICE)
- NNT, *see* number needed to treat (NNT), concepts
- Noisy phenomenon, intention-to-treat analysis, 110–12
- Non-compliance problems, *see* Compliance issues
- Non-directive counselling, 48, 77–8
- Non-ignorable dropouts, 104–7
- Northwick Park Hospital, TGN 1412 trial, 164, 171–3
- Nortriptyline, 45
- Nuisance parameters, 100
- Null hypothesis
meta-analyses, 153–5
p-values, 90–1, 93–7, 117, 125–44, 200
- Number needed to treat (NNT), concepts, 116
- Nuremberg Code, 33–4
- Oakes, M., 90–1, 147, 200
- Objective/subjective outcome measures, 85–7
- O'Brien–Fleming critical values, 68–70
- Observational trials, 169–70
- Observer-rated scales
concepts, 85–6
see also Hamilton Rating Scale for Depression (HRSD)
- Ogundipe *et al.*, 61–2
- Olanzapine, 45, 91
- Opportunity costs, 113
- OSWALD, 203
- Outcome measures
baseline data, 91–7, 123–44
clinical trials, 17, 26, 44, 64–5, 81–7, 91–117, 120–44, 151–2, 176–7, 184–93, 195–200
concepts, 81–7, 91–117, 120–44, 151–2, 184–93
critique, 81–7, 195–200
depression, 82–4, 120–44, 176–7
examples, 120–44, 154–62
follow-up measures, 87, 120–44, 191
KISS, 84, 168, 174–5, 185
multiple outcome measures, 108–9, 120–44, 151–2
objective/subjective measures, 85–7
primary outcome measures, 85–7
psychiatric trials, 81–7, 120–44, 154–62, 184–93, 195–200
schizophrenia, 83–7, 177
secondary outcome measures, 85–7
suitability issues, 82–6
time factors, 86–7, 120–44
variety, 84–6
- Oxford Group, 175–6
- P-values
concepts, 90–1, 93–7, 117, 125–44, 200
definition, 90
- Palmer, C.R., 40–1, 163
- Parachute analogy, 13
- Parallel groups, concepts, 44–5
- Pare, Ambroise, 3
- Parkinson's Disease, 79
- Participants, compliance issues, 36–40
- Patient information sheets, concepts, 188–9
- Patient preference trials, concepts, 46–8, 78, 169
- Peduzzi *et al.*, 110–11
- Penicillin, 13, 29, 175
- Peptic ulcers, 43
- Permuted block randomization, *see* Blocked randomization
- Pharmaceutical companies, suspicions, 164, 170–1
- Pharmacology
historical background, 5, 6–7, 10–11, 21
see also Drugs
- Pharmacy-controlled methods, allocation concealment, 62
- Phase 1 trials, concepts, 27–8, 79–81
- Phase 2 trials, concepts, 28, 79–81
- Phase 3 trials, concepts, 28, 79–81, 136
- Phase 4 trials, concepts, 28–9, 79–81
- Physical therapies, historical background, 8–10
- Physicians, Hippocratic oath, 2
- Physician's friend, 14
see also Regression to the mean
- Piantadosi, S., 182
- Pickering, G.W., 15–16
- Pill/capsule counts, compliance issues, 39
- Placebo effects
concepts, 14, 17–18, 19, 27, 30–1, 46, 47, 74, 94–5, 170–1, 180
ethical issues, 30–1
schizophrenia, 14
treatments, 14, 17–18, 19, 27, 30–1, 46, 47, 74, 94–5, 170–1, 180
- Pocock, S.J., 64–6, 68, 91–2, 93, 95–7, 108–9, 131, 148–9
- Poisson distribution, 70
- Polio, 11
- 'Pores', heart, 1
- Possible measure, summary measure approach, 98–9, 131–5
- Post-traumatic stress disorder (PTSD), 24, 30, 83–4
debriefing procedure, 24, 30
treatments, 24, 30, 83–4
- Post-treatment BDI scores, analysis example, 123–35

- Postmarketing surveillance, drugs, 28, 79–80
- Pragmatic trials
 concepts, 27, 47–8, 72–8, 168–9
 critique, 72–8, 168–9
 depression treatments, 77–8
 eligibility criteria, 72–3
 examples, 77–8
 explanatory trials, 72–8, 168–9
see also Effectiveness trials; Large simple randomized trials
- Preferences, patient preference trials, 46–8, 78, 169
- Primary care settings, depression, 73, 76–8, 120, 123, 139–44
- Primary outcome measures, 85–7
see also Outcome measures
- Private practice, critique, 33
- Prognostic factors, concepts, 58–62
- Proudford *et al*, 120
- Prozac, 156
- Psychiatric trials
 analyses, 89–117, 119–44, 154–62, 163–80, 200
 challenges, 163–80
 complex interventions, 79–81, 166–8, 174
 complex problems, 71–2, 79–81, 135–44, 166–8, 174
 compliance issues, 39–40, 46, 186–7
 concepts, 5–11, 21–4, 39–40, 69, 71–87, 89–117, 119–44, 154–62, 163–80
 cost-effectiveness analysis, 113–15, 185–6
 critique, 71–87, 163–80
 defences, 178–80
 definitions, 5–6
 dropouts, 103–7, 111–12, 117, 119–44, 202–3
 economic evaluations, 112–15
 effectiveness RCTs, 73–8, 112–15
 examples, 119–44, 154–62
 explanatory/pragmatic trials, 72–8, 168–9
 first modern trials, 21–4
 future prospects, 163–4, 173–80
 historical background, 5–11, 21–4
 individual interventions, 165–6
 interim analyses, 69–70, 202–3
 justification debate, 164–9
 longitudinal data, 64, 97–103, 117, 119–44
 meta-analyses, 154–62
 mortality endpoints, 69, 82
 necessity debate, 169–70
 number needed to treat, 116
 outcome measures, 81–7, 120–44, 154–62, 184–93, 195–200
 pragmatic trials, 72–8, 168–9
 RCT generalizations, 71–3, 116, 164–80
 simple problems, 71–2
 special problems, 71–87
 specialist settings, 73, 76–8
 statistical issues, 89–117, 119–44, 154–62, 200
 threats, 163–80
 ‘wish list’, 174–5
see also Clinical trials
- Psychopathology, 83–4
- Psychoses, 27, 31, 73, 83–7, 114, 177
 outcome measures, 83–7, 177
see also Schizophrenia
- Psychotherapies, 26, 81
- PTSD, *see* Post-traumatic stress disorder (PTSD)
- Public perceptions, clinical trials, 163–4, 171–3, 180
- Publication bias, meta-analyses, 151–3, 158–61, 173
- Pulmonary tuberculosis, 21
- Purgatives, 2, 5, 6
- Pythagoreans, 6
- Qualitative methods, 146–8, 174–5
- Quality of life (well being), 82–3, 85, 178, 180
- Quality selection component, meta-analyses, 148–9
- Quantitative component
 systematic reviews, 146–8
see also Meta-analyses
- Questionnaire measures, depression, 82
- Quitkin, Fred, 31
- Raleigh’s antidote, 3
- Random effects models
 Beating the Blues analysis example, 135–44
 dropouts, 107, 142–4
 longitudinal data, 99–103, 107, 117, 135–44
 meta-analyses, 153–5
 surgery effects, 139–44
- Random intercept model, concepts, 100–3, 137–42
- Random intercept and slope model, concepts, 100, 102–3, 138–42
- Random numbers, blocked randomization, 57–8
- Randomization techniques, concepts, 19–23, 44–5, 56–62, 149–50, 169–70, 179–80, 182–93
- Randomized clinical (controlled) trials (RCTs)
 advantages, 22–4, 40–1, 163–80
 Beating the Blues analysis example, 119–44
 blinding, 25–6, 44, 74–6, 79, 113, 149–50, 156–8, 180
 challenges, 163–80
 cluster trials, 51–3
 complex interventions, 79–81, 166–8, 174
 complications, 56–62, 79–81
 computer software, 61, 68, 106, 120–44, 201–3
 concealment considerations, 23, 25–6, 62, 176, 199–200
 concepts, 19–41, 71–87, 163–80, 181–93
 conflicts of interest, 164, 170–1
 critique, 22–4, 29–30, 32–3, 40–1, 71–87, 163–80, 195–6
 defences, 178–80
 definition, 19

- economic evaluations, 112–15
 ethical issues, 21, 29–33, 35–6, 41, 46–8, 66,
 67–70, 163–4, 188
 examples, 119–44, 154–62
 first modern trials, 20–2
 future prospects, 163–4, 173–80
 generalizations, 71–3, 115, 164–80
 Hill's first modern trial, 20–1
 historical background, 19–24, 79, 176
 'how to do it' guide, 181–93
 informed consent, 35–6, 48–51, 164, 178–80,
 189–90
 justification debate, 164–9
 management issues, 181–93
 methods, 56–62, 181–93, 199–200
 necessity debate, 169–70
 patient preference trials, 48, 78, 169
 psychiatric trials, 21–4, 71–87, 89–117, 119–44,
 154–62, 163–80
 quality assessments, 25, 73–8
 schizophrenia, 22, 27, 35, 45, 69, 73, 166–7, 177
 'silver standard', 180
 techniques, 19
 threats, 163–80
 trial protocol, 70, 181–93
 trial reports, 195–200
 Zelen's design, 48–51
see also Clinical trials
- Randomized encouragement trials, concepts, 50–1
 RCTs, *see* Randomized clinical (controlled) trials
 (RCTs)
- Recruitment issues, 29, 44, 61–2, 63–6, 72–3, 74,
 77, 174, 180, 190
 size considerations, 61–2, 63–6, 74, 77, 174
 tips, 190
see also Multicentre trials
- Rectangular data matrix, 105, 106–7
- Rees, Linford, 22
- Referrals, depression, 120
- Reflexology, 156
- Registration issues, meta-analyses, 161–2
- Regression analysis, 14, 17, 89, 94–103, 107,
 126–8, 136–44, 154–6
- Regression to the mean, 14, 17, 94–5
- Regulations, 178–9, 186–7, 189–90
- Religion, 6
- Repetitive TMS (rTMS), 158–60
- Representativeness selection component,
 meta-analyses, 148–9, 151–3
- Response feature analysis
 longitudinal data, 97–9, 131–44
see also Summary measure approach
- Rheumatoid arthritis, 86–7
- Rice, beriberi, 20
- Risperidone, 45
- Robust data, 125, 186–7
- Roland, M., 72
- Rothman, Ken, 31
- Royal Free Hospital, London, patient preferences,
 47–8
- Royal Society of Medicine, 16
- rTMS, *see* Repetitive TMS (rTMS)
- Rubin, D.B., 103–4
- S-PLUS, 203
- Sacks *et al*, 169
- St John's wort, depression, 156–8, 175
- Samaritans, 15–16
- Samples, size issues, 61–2, 63–6, 74, 77, 174–8,
 182–93, 196–200, 202–3
- Sapirstein, G., 150
- Sargent, William, 9, 41
- SAS, 201–3
- Scandals, clinical trials, 163–4, 171–3, 180
- Scarborough, Doctor, 2–3
- Scarlet fever, 20
- Schafer, J.L., 105–6
- Schizophrenia, 11, 13, 14, 22, 27, 35, 40, 45, 69,
 73, 83–7, 91, 158, 166–7, 177
 complexity factors, 166–7
 compliance therapy, 40
 mortality endpoints, 69
 outcome measures, 83–7, 177
 placebo effects, 14
 randomized clinical (controlled) trials, 22, 27, 35,
 45, 69, 73, 158, 166–7, 177
 treatments, 91, 158, 177
see also Psychoses
- Schou, Morgens, 22
- Screening for breast cancer, 170
- Scurvy, 3–5
- Secondary outcome measures
 concepts, 85–7
see also Outcome measures
- Secretin, 45–6
- Selection bias, concepts, 14–15, 17, 18–19, 22–4,
 25, 48–50, 76, 85–6, 174, 179
- Selective serotonin reuptake inhibitors (SSRIs), 10,
 172, 176
- Self-rated questionnaires, depression, 86
- Senn, S., 64–6, 94–5, 116
- Sequentially numbered containers, allocation
 concealment, 62
- Sequentially numbered, opaque sealed envelopes
 (SNOSE), allocation concealment, 62
- Serotonin, 10
- Sertraline, 45
- Sharp, S.M., 70
- Shepherd, Michael, 10, 22
- Shi, J.Q., 153, 160
- Side effects, drugs, 26, 27–8, 187–8
- Silberschatz, G., 165

- 'Silver standard', randomized clinical (controlled) trials, 180
- Silverman, W.A., 18
- Simon, G., 115
- Simon, R., 65
- Simon, S.D., 180
- Simple problems, psychiatric trials, 71–2
- Simplicity needs, KISS, 84, 168, 174–5, 185
- Single-blind studies
 - concepts, 26
 - see also* Blinding
- Single patient trials, *see* N-of-1 trials
- Size issues, 61–2, 63–6, 74, 77, 174–8, 182–93, 196–200, 202–3
 - examples, 63–4
 - small samples, 65–6, 178
 - statistics, 63–5, 74, 77–8, 174–8, 182–93, 196–200, 202–3
- Slade, Mike, 71, 81–2
- Smithells, R., 33
- Smoking
 - Down's syndrome, 96
 - expectant mothers, 51, 96
- SNOSE, *see* sequentially numbered, opaque sealed envelopes (SNOSE), allocation concealment
- Software, *see* Computer software
- SOLAS, 203
- Specialist settings, clinical trials, 73, 76–8
- Spilker, B., 169
- Sponsors, conflicts of interest, 170–1
- Spontaneous improvements, mental disorders, 14, 17
- SPSS, 201–2
- SSRIs, *see* Selective serotonin reuptake inhibitors (SSRIs)
- Staff factors
 - clinical trials, 38, 112–15, 179, 185–6
 - compliance issues, 38
- STATA, 201–3
- Statistical Methods for Research Workers* (Fisher), 90
- Statistics
 - baseline data, 91–7, 123–44
 - computer software, 61, 68, 106, 120–44, 201–3
 - concepts, 63–5, 67, 89–117, 174–9, 200, 201–3
 - confidence intervals, 90–1, 125–44, 153–62
 - cost-effectiveness analysis, 113–15, 185–6
 - critique, 64–5, 67, 89–117, 174–9, 200
 - dropouts, 103–7, 111–12, 117, 119–44, 202–3
 - economic evaluations, 112–15
 - imputation techniques, 105–7, 202–3
 - intention-to-treat analysis, 78, 109–12, 117, 176
 - interim analyses, 66–70, 202–3
 - longitudinal data, 64, 97–103, 117, 119–44
 - meta-analyses, 153–62, 178
 - missing values, 103–7, 123–44, 202–3
 - multiple outcome measures, 108–9, 120–44, 151–2
 - number needed to treat, 116
 - p-values, 90–1, 93–7, 117, 125–44, 200
 - psychiatric trials, 89–117, 119–44, 154–62
 - random effects models, 99–103, 107, 117, 135–44, 153–6
 - size issues, 63–5, 74, 77–8, 174–8, 182–93, 196–200, 202–3
- Sternback, Leo, 10
- Stochastic theory, 10
- Stopping rules, 66–70
- Stratified analysis, 60
- Stratified randomization
 - concepts, 58–61
 - critique, 59–60
- Streptomycin, 21
- Stroke patients, 50, 84
- Stromgren, Eric, 22
- Structured interviews, 74
- Study-selection issues, systematic reviews, 148–51, 158–9
- Subgroup analysis, baseline data, 91–3, 123–44
- Subjective outcome measures, 85–7
- Substance abuse, 166–7
- Suicides, 15–16, 53, 69–70, 73, 172–3
 - declining rates, 15–16
 - interim analyses, 69–70
 - natural gas, 15
 - SSRIs, 172–3
- Summary measure approach
 - Beating the Blues analysis example, 128–36
 - dropouts, 107
 - longitudinal data, 97–9, 107, 124–36
 - possible measure, 98–9, 131–5
 - see also* Response feature analysis
- Surgery effects, random effects models, 139–44
- Suspensions, pharmaceutical companies, 164, 170–1
- Sutherland, Stuart Professor, 5–6
- Symptoms
 - depression, 14
 - overestimated importance, 84
- Syphilis, 66
- Systematic reviews, 66, 145–62
 - aims, 147–8
 - breadth selection component, 148–9
 - components, 146–8
 - concepts, 66, 145–62, 181
 - databases, 149–51, 156–7, 158–62, 181
 - examples, 150–1, 154–62
 - qualitative component, 146–8
 - quality selection component, 148–9
 - quantitative (meta-analysis) component, 146–8

- representativeness selection component, 148–9, 151–3
- study-selection issues, 148–51, 158–9
- see also* Meta-analyses
- t-tests, 89, 98–9, 109, 125–44
- TAU, *see* Treatment as usual approaches (TAU)
- Termination issues, clinical trials, 66–70
- Tests on blood/urine, compliance issues, 39
- TGN 1412 trial, 164, 171–3
- Thalidomide, 10
- Therapeutics, 16
- Threats, clinical trials, 163–80
- Thrombolytic therapy, 43
- Time factors, 64, 66–70, 71–2, 74, 86–7, 97–103, 120–44, 182–93
 - longitudinal data, 64, 97–103
 - outcome measures, 86–7, 120–44
- TMS, *see* Transcranial magnetic stimulation (TMS), depression
- Torgerson, D., 72
- Toxicity, clinical trials, 27–8
- Tracing consent, 87
- Tracking concepts, 129–35
- Training, GP training, 170
- Transcranial magnetic stimulation (TMS), depression, 158–60
- Transparency issues, 172–3, 179
- Trauma disorders, 24, 30, 83–4
 - see also* Ppost-traumatic stress disorder (PTSD)
- A Treatise on the Scurvy* (Lind), 4
- Treatment as usual approaches (TAU), 120–44
- Treatment fidelity, 81
- Treatment groups
 - clinical trials, 17–24, 44–55, 91–7
 - concepts, 17–18, 44–55
 - definition, 17
 - parallel groups, 44–5
 - randomization techniques, 19–23, 44–5, 56–62, 149–50, 169–70, 179–80, 182–93
- Treatment-received approach, 109–12
- Treatments
 - alternative therapies, 33, 155–8
 - anxiety, 10, 11, 22, 166–7
 - Asher's paradox, 33
 - assessments, 1–11
 - Beating the Blues analysis example, 119–44
 - behavioural psychotherapy, 11
 - blood-letting, 2, 5, 6, 14, 19, 20
 - CBT, 40, 48, 78–80, 114, 119–44
 - CFS, 26
 - clinical governance, 32–3, 188–90, 193
 - cognitive therapy, 11
 - combinations, 46
 - competing treatments, 4–5, 16
 - compliance issues, 36–40, 46
 - confounders, 14–15, 23–4, 48
 - cost-effectiveness analysis, 113–15, 185–6
 - depression, 9, 10, 11, 13, 17, 22, 30–2, 45, 47, 61, 73, 76–8, 82–6, 119–44, 150–1, 155–62, 166–7, 172–3, 175, 176–7
 - economic evaluations, 112–15
 - efficacy/effectiveness trials, 27–8, 31–2, 43–4, 72–8, 112–15, 168–9
 - ethical issues, 17, 21, 29–33, 46–8, 66, 67–70, 188
 - evaluations, 4–5, 10–11, 13, 28–41, 79–81, 112–15
 - fashions, 2
 - historical background, 1–11, 15–16, 19–24
 - informed consent, 21, 30, 33–6, 48–51, 164, 178–80, 189–90
 - intention-to-treat analysis, 78, 109–12, 117, 176
 - mania, 158
 - manic depression, 10, 73, 177
 - mental illness, 5–11, 13–41, 71–87
 - motivational interviewing, 40
 - number needed to treat, 116
 - placebo effects, 14, 17–18, 19, 27, 30–1, 46, 47, 74, 94–5, 170–1, 180
 - primary care settings, 73, 76–8, 120, 123, 139–44
 - PTSD, 24, 30, 83–4
 - regression to the mean, 14, 17, 94–5
 - St John's wort, 156–8, 175
 - schizophrenia, 91, 158, 177
 - selection bias, 14–15, 17, 18–19, 22–4, 25, 48–50, 76, 85–6, 174, 179
 - spontaneous improvements, 14, 17
 - TMS, 158–60
 - worthless treatments, 1–5
- Trial protocol, concepts, 70, 181–93
- Trial reports, 195–200
- Trials, *see* Clinical trials
- Tricyclic antidepressants, 10, 157–8, 176–7
- Triple-blind studies
 - concepts, 26
 - see also* Blinding
- True causes, heterogeneity, 154–6
- Tuberculosis, 21
- Tuskegee Syphilis Study, 66
- Tweedie, R.L., 151–3
- Type, 1 errors, 63–8, 108, 111, 200
- Type, 2 errors, 20, 65–6
- UK, 50, 69–70, 175–6, 177–8, 184–7, 191–3, 201–3
 - Daily Living Programme (DLP), 69–70
 - Medicines for Human Use (Clinical Trials) Regulations 2004, 50
 - NHS, 185, 187, 191–2
 - Oxford Group, 175–6
 - 'UK 700' study, 177

- Unconditional mean, imputation techniques, 106
- US
 Department of Health and Human Services, 50
 Food and Drug Administration, 50, 161
- Valproate, 177
- Vesalius, Andreas, 1
- Violent offenders, 167
- Vitamin C, scurvy, 3–4
- Warlow, Charles, 84
- Web sites, 191–3, 201–3
- Well being (quality of life), 82–3, 85, 178, 180
- Wells, K.B., 78
- WHO, *see* World Health Organization (WHO)
- Whooping cough, 11, 21
- Willow trees, 5
- ‘Wish list’, psychiatric trials, 174–5
- World Bank, 176
- World Health Organization (WHO), 160–1
- Worthless treatments, 1–5
- ‘Wrong’ answers, clinical trials, 175–6
- Zelen’s design, concepts, 48–51